Rifapentine is active in vitro and in vivo against Toxoplasma gondii | Zendy

Fausto G. Araujo | Zendy; Anis A. Khan | Zendy; J S Remington | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rifapentine is active in vitro and in vivo against Toxoplasma gondii

Author(s) -

Fausto G. Araujo,

Anis A. Khan,

J S Remington

Publication year - 1996

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.40.6.1335

Subject(s) - rifapentine , rifamycin , toxoplasma gondii , in vivo , rifabutin , microbiology and biotechnology , in vitro , cytotoxic t cell , biology , toxoplasmosis , virology , immunogenicity , antibacterial agent , pharmacology , antibiotics , immunology , antigen , medicine , antibody , mycobacterium tuberculosis , tuberculosis , pathology , biochemistry , clarithromycin , latent tuberculosis

Rifapentine, a derivative of rifamycin, was examined for its in vitro and in vivo activities against the protozoan parasite Toxoplasma gondii. The drug inhibited the intracellular replication of parasites and was not cytotoxic for the host cells at inhibitory concentrations. Mice infected either intraperitoneally with tachyzoites of the RH strain or orally with tissue cysts of the C56 strain were protected against death by treatment with rifapentine. The degree of protection was similar to that induced by atovaquone and apparently higher than that induced by rifabutin. Rifapentine may be a useful drug for the treatment of toxoplasmosis in immunocompromised individuals.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research